Clinical trial

Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

NCT01696643

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention CB-5945 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2012-10-12

PhasePHASE3

Conditions

Opioid-Induced Constipationverified · MONDO: opioid-induced constipation

Interventions

CB-5945DRUG

PlaceboDRUG

Sponsors & collaborators

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01696643 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.